EP4032884A1 - Cristal de dérivé de 1,3,5-triazine ou solvate de celui-ci et son procédé de production - Google Patents

Cristal de dérivé de 1,3,5-triazine ou solvate de celui-ci et son procédé de production Download PDF

Info

Publication number
EP4032884A1
EP4032884A1 EP20865547.2A EP20865547A EP4032884A1 EP 4032884 A1 EP4032884 A1 EP 4032884A1 EP 20865547 A EP20865547 A EP 20865547A EP 4032884 A1 EP4032884 A1 EP 4032884A1
Authority
EP
European Patent Office
Prior art keywords
formula
compound represented
crystal
compound
salt
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
EP20865547.2A
Other languages
German (de)
English (en)
Other versions
EP4032884A4 (fr
Inventor
Hiroyuki Kai
Toshikatsu Maki
Shinichi Oda
Kazunori Ban
Koichi Tsubone
Masahiro Hosoya
Yuki Murakami
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Shionogi and Co Ltd
Original Assignee
Shionogi and Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Shionogi and Co Ltd filed Critical Shionogi and Co Ltd
Publication of EP4032884A1 publication Critical patent/EP4032884A1/fr
Publication of EP4032884A4 publication Critical patent/EP4032884A4/fr
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C227/00—Preparation of compounds containing amino and carboxyl groups bound to the same carbon skeleton
    • C07C227/04—Formation of amino groups in compounds containing carboxyl groups
    • C07C227/06—Formation of amino groups in compounds containing carboxyl groups by addition or substitution reactions, without increasing the number of carbon atoms in the carbon skeleton of the acid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C227/00—Preparation of compounds containing amino and carboxyl groups bound to the same carbon skeleton
    • C07C227/04—Formation of amino groups in compounds containing carboxyl groups
    • C07C227/06—Formation of amino groups in compounds containing carboxyl groups by addition or substitution reactions, without increasing the number of carbon atoms in the carbon skeleton of the acid
    • C07C227/08—Formation of amino groups in compounds containing carboxyl groups by addition or substitution reactions, without increasing the number of carbon atoms in the carbon skeleton of the acid by reaction of ammonia or amines with acids containing functional groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C227/00—Preparation of compounds containing amino and carboxyl groups bound to the same carbon skeleton
    • C07C227/14—Preparation of compounds containing amino and carboxyl groups bound to the same carbon skeleton from compounds containing already amino and carboxyl groups or derivatives thereof
    • C07C227/18—Preparation of compounds containing amino and carboxyl groups bound to the same carbon skeleton from compounds containing already amino and carboxyl groups or derivatives thereof by reactions involving amino or carboxyl groups, e.g. hydrolysis of esters or amides, by formation of halides, salts or esters
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C229/00—Compounds containing amino and carboxyl groups bound to the same carbon skeleton
    • C07C229/02—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton
    • C07C229/04—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated
    • C07C229/06—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having only one amino and one carboxyl group bound to the carbon skeleton
    • C07C229/08—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having only one amino and one carboxyl group bound to the carbon skeleton the nitrogen atom of the amino group being further bound to hydrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C229/00—Compounds containing amino and carboxyl groups bound to the same carbon skeleton
    • C07C229/02—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton
    • C07C229/04—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated
    • C07C229/06—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having only one amino and one carboxyl group bound to the carbon skeleton
    • C07C229/10—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having only one amino and one carboxyl group bound to the carbon skeleton the nitrogen atom of the amino group being further bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings
    • C07C229/14—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having only one amino and one carboxyl group bound to the carbon skeleton the nitrogen atom of the amino group being further bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings to carbon atoms of carbon skeletons containing rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C309/00—Sulfonic acids; Halides, esters, or anhydrides thereof
    • C07C309/01—Sulfonic acids
    • C07C309/28—Sulfonic acids having sulfo groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton
    • C07C309/29—Sulfonic acids having sulfo groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton of non-condensed six-membered aromatic rings
    • C07C309/30—Sulfonic acids having sulfo groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton of non-condensed six-membered aromatic rings of six-membered aromatic rings substituted by alkyl groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/05—Isotopically modified compounds, e.g. labelled
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Definitions

  • the present invention relates to a crystal of a 1,3,5-triazine derivative or a solvate thereof and a pharmaceutical composition containing the same.
  • the present invention relates to a method for producing a crystal of a 1,3,5-triazine derivative or a solvate thereof and a pharmaceutical composition containing the same.
  • Adenosine triphosphate is known as an intracellular energy source and a phosphorylated substrate. On the other hand, it is also known to act as an extracellular information transmitter. Furthermore, it is known that ATP is released to the outside of cells by various stimuli such as cell damage, inflammation, noxious stimuli, and reduction in blood oxygen level, and that ATP is released to the outside of cells from primary sensory nerve endings together with other neurotransmitters. ATP released to the outside of cells performs various kinds of extracellular information transmission via an ATP receptor (Non-Patent Document 4, Non-Patent Document 5).
  • Non-Patent Document 6 ATP receptors are roughly classified in the ion channel P2X family and the G protein coupled P2Y family.
  • the P2X receptor family is reported to have seven subtypes, which form a homotrimer or a heterotrimer with other P2X subtypes to function as a non-selective cation channel (Non-Patent Document 6).
  • Non-Patent Document 1 Non-Patent Document 1
  • the compound having P2X 3 or P2X 2/3 receptor antagonistic action is suggested to be useful in: pain treatment (Patent Document 1, Non-Patent Document 3, and Non-Patent Document 7); treatment of diseases associated with dysfunctional voiding (Non-Patent Document 2); treatment of respiratory diseases (Non-Patent Document 8, Non-Patent Document 9, Non-Patent Document 10, Patent Document 2, and Patent Document 3); treatment of chronic cough (Patent Document 4, Patent Document 5, and Non-Patent Document 11); treatment of hypertension (Non-Patent Document 12); Treatment of pain associated with pancreatitis (Non-Patent Document 13); and treatment of pain associated with endometriosis (Non-Patent Document 14, and Non-Patent Document 15).
  • Patent Document 6 describes that a 1,3,5-triazine derivative represented by the following formula has P2X 3 and/or P2X 2/3 antagonistic action, and is useful for treatment and/or prevention of pain:
  • Patent Document 7 describes that a 1,3,5-triazine derivative represented by the following formula has P2X 3 and/or P2X 2/3 antagonistic action, and is useful for treatment and/or prevention of pain:
  • Patent Document 8 describes that a 1,3,5-triazine derivative represented by the following formula has P2X 3 and/or P2X 2/3 antagonistic action, and is useful for treatment and/or prevention of pain:
  • Patent Document 9 describes that a 1,3,5-triazine derivative represented by the following formula has P2X 3 and/or P2X 2/3 antagonistic action, and is useful for treatment and/or prevention of pain:
  • Patent Documents 6, 7, 8, and 9 disclose a method for producing a 1,3,5-triazine derivative, but do not describe the process according to the present invention, and disclose only a method for producing a similar compound.
  • Patent Document 10 discloses a 1,3,5-triazine derivative exhibiting a therapeutic effect on chronic cough, but does not describe a crystal and a process according to the present invention.
  • Non-Patent Document 16 discloses an aza-Michael addition reaction of (S)-1-phenylethylamine and methyl methacrylate.
  • the pharmaceutically active ingredients may have substantially different physical properties depending on the respective solid form. Such differences in physical properties may affect, for example, the method of making or administering a pharmaceutically active ingredient, or a pharmaceutical composition comprising the pharmaceutically active ingredient.
  • the present invention relates to crystal of a 1,3,5-triazine derivative or a solvate thereof that is very useful as compared to other solid forms in a method for producing or administering a pharmaceutically active ingredient, or in a pharmaceutical composition comprising a pharmaceutically active ingredient.
  • an object of the present invention is to provide a crystalline form having good physical properties as a drug substance for the compound represented by Formula (I).
  • Patent Document 9 does not describe a method for producing the compound I-127, but as a similar compound, Reference Example 3 of Patent Document 9 discloses a method for producing a 1,3,5-triazine derivative as shown in the following formula. However, the process is not yet sufficient, and can be improved further.
  • the inventors of the present invention have found that, as crystalline forms of the compound represented by Formula (I), there are crystalline forms of an anhydrous Form I, an anhydrous Form II, and a dihydrate. Furthermore, they have found that the anhydrous crystal Form I and the dihydrate crystal are more stable than other crystal forms. In addition, they have found that the anhydrous crystal Form I has a low Compressibility index (%) of the crystal and has a favorable crystal fluidity as compared with other crystal forms.
  • the present inventors have found an intermediate having a high chemical purity and/or optical purity, a method for producing the intermediate, and a method for producing an optically active 1,3,5-triazine derivative having P2X 3 and/or P2X 2/3 antagonistic action.
  • the present invention relates to the following items (1'), (2'), (2'A), (2'B), (3'), (3'A), (3'B), (4') to (35'), (3"), (5"), and (36") to (42").
  • the present invention also relates to the following items (1) to (34).
  • a crystal of the present invention is useful as an active pharmaceutical ingredient of a compound represented by Formula (I). That is, the pharmaceutical composition containing a crystal of the present invention is very useful as a therapeutic agent or a prophylactic agent for chronic cough or refractory chronic cough.
  • an anhydrous crystal Form I and a dihydrate crystal are useful as active pharmaceutical ingredients.
  • anhydrous crystal Form I has the following characteristics:
  • the dihydrate crystal has the characteristics of the above (ii) and (iii).
  • a process method of the present invention can produce compounds useful as process intermediates, represented by Formula (IV) and Formula (V), and a compound represented by Formula (I) and a crystal thereof.
  • the present process method is an industrially excellent process method, and the characteristics of the process method of the present invention can include the following points:
  • the selection and control of the solid form is important, especially for a compound as a drug. Careful selection and control of the solid form can reduce problems in production, formulation, or administration related with the compound.
  • a numerical value in the present specification and claims is an approximate value.
  • a numerical change originates from a device calibration, a device error, substance purity, a crystal size, a sample size, temperature, and other factors.
  • crystal used in the present specification means a solid in which atoms, ions, molecules, and the like constituting the crystal are three-dimensionally and regularly arranged, and is distinguished from an amorphous solid not having such a regular internal structure.
  • the crystal of the present invention may be a single crystal, a twin crystal, a polycrystal, or the like.
  • crystal polymorphs may be present in “crystals”. They are collectively referred to as “crystalline forms” and are intended to be included in the present invention.
  • the "compound represented by Formula (I)" can form a solvate with water (that is, a hydrate) or a solvate with a general organic solvent, and such a solvate is also intended to be included within the scope of the present invention.
  • the crystalline form and the crystallinity can be measured by many techniques including, for example, powder X-ray diffractometry, Raman spectroscopy, infrared absorption spectroscopy, moisture adsorption/desorption measurement, differential scanning calorimetry, and dissolution characteristics.
  • salt used in the present specification means, for example, that the "compound represented by Formula (I)" and counter molecules are regularly arranged in the same crystal lattice, and any number of counter molecules may be included.
  • the term refers to one in which an ionic bonding is mediated by proton transfer between a compound and a counter molecule in a crystal lattice.
  • salt formation provides a means to alter physicochemical characteristics of an agent and resulting biological characteristics without altering its chemical structure.
  • Salt formation can have a dramatic impact on properties of the agent.
  • hygroscopicity, stability, solubility and processing properties of the salt are also important aspects.
  • a solubility of a salt can affect its suitability for use as an agent. If the aqueous solubility is low, the dissolution rate in in vivo administration is limited by the absorption process and may result in low bioavailability. In addition, the low aqueous solubility may make it difficult to administer by injection, and therefore, the selection of an appropriate administration route may be limited.
  • the "compound represented by Formula (I)" may be converted into a solvate, a pharmaceutically acceptable salt, or a solvate of a salt.
  • the compound is in the form of a base addition salt.
  • the base addition salt include salts made from pharmaceutically acceptable non-toxic bases including inorganic and organic bases.
  • the salt derived from inorganic bases include, but are not limited to, salts of aluminum, calcium, lithium, potassium, magnesium, sodium, zinc, and other metal salts.
  • Examples of a pharmaceutically acceptable salt based on a non-toxic base include salts of primary, secondary or tertiary amines, and substituted amines including naturally occurring substituted amines, cyclic amines and basic ion exchange resins, such as, arginine, betaine, benzathine, caffeine, choline, chloroprocaine, cycloprocaine, N'N'-dibenzylethylenediamine, diethanolamine, diethylamine, 2-diethyl-aminoethanol, 2-dimethylaminoethanol, ethanolamine, ethylenediamine, N-ethyl-morpholine, N-ethylpiperidine, glucamine, glucosamine, histidine, hydrabamine, isopropylamine, lysine, meglumine, morpholine, piperazine, piperidine, polyamine resins, procaine, purines, tertiary butylamine (2-methylpropane-2
  • Examples of the acid addition salts of "the compound represented by Formula (I)", “the compound represented by Formula (II)”, “the compound represented by Formula (IV)", “the compound represented by Formula (IV-A)", “the compound represented by Formula (IV-B)” and “the compound represented by Formula (V)” include a compound having:
  • solvate used in the present specification refers to, for example, one that is regularly arranged with an arbitrary number of solvent molecules with respect to the "compound represented by Formula (I)".
  • solvent molecule examples include acetonitrile, chlorobenzene, chloroform, cyclohexane, 1,2-dichloroethene, dichloromethane, 1,2-dimethoxyethane, N,N-dimethylacetamide, N,N-dimethylformamide, 1,4-dioxane, 2-ethoxyethanol, ethylene glycol, formamide, hexane, methanol, 2-methoxyethanol, methylbutyl ketone, methylcyclohexane, N-methylpyrrolidone, nitromethane, pyridine, sulfolane, tetralin, toluene, 1,1,2-trichloroethene, xylene, acetic acid, anisole, 1-butanol, 2-butanol, t-butanol, n-butyl acetate, t-butyl methyl ether, cumene, dimethyl sulfoxide,
  • Preferred examples include acetic acid, anisole, 1-butanol, 2-butanol, n-butyl acetate, t-butyl methyl ether, cumene, dimethyl sulfoxide, ethyl acetate, diethyl ether, ethyl formate, formic acid, heptane, isobutyl acetate, isopropyl acetate, methyl acetate, 3-methyl-1 butanol, methyl ethyl ketone, methyl isobutyl ketone, 2-methyl-1-propanol, pentane, 1-pentanol, 1-propanol, 2-propanol, propyl acetate, tetrahydrofuran, water (i.e., hydrate), ethanol, acetone, 1,1-diethoxypropane, 1,1-dimethoxymethane, 2,2-dimethoxypropane, isooctane, isopropy
  • More preferred examples thereof include water (i.e., hydrate), ethanol, acetone, 1,1-diethoxypropane, 1,1-dimethoxymethane, 2,2-dimethoxypropane, isooctane, isopropyl ether, methyl isopropyl ketone, methyl tetrahydrofuran, petroleum ether, trichloroacetic acid, and trifluoroacetic acid.
  • the hydrate of the present invention or the crystal thereof contains, for example, about 2 molar equivalents of water molecules with respect to "the compound represented by Formula (I)".
  • Preferable examples of the hydrate crystal of the present invention include a dihydrate.
  • the hydrate of the present invention or the crystal thereof has a water content of, for example, 4.7 to 9.7 wt%.
  • the water content is about 5.6 to 7.6 wt% (the theoretical value of the dihydrate is 6.6%, but the moisture content may increase due to the influence of water adhering to the crystal, or a part of water in the crystal may be desorbed before measurement whereby the moisture content may decrease.).
  • the crystal of the present invention may be a deuterium conversion product.
  • the crystal of the present invention may be labeled with an isotope (examples: 3 H, 14 C, 35 S, 125 I).
  • anhydride used in the present specification is synonymous with “ansolvate”, “non-solvate,” “anhydrate,” and “non-hydrate”.
  • the compound represented by Formula (I) is a P2X 3 and/or P2X 2/3 antagonist described in Patent Document 9:
  • a tautomer of the compound represented by Formula (I) is a compound (amino form) represented by Formula (I'):
  • This compound has a P2X 3 and/or P2X 2/3 receptor antagonistic action, like the compound represented by Formula (I).
  • the compound represented by Formula (I) may also include a mixture of the compound represented by Formula (I) (imino form) and the compound represented by Formula (I') (amino form), and they may be mixed at an arbitrary ratio. The same applies to the compound represented by Formula (VI).
  • anhydrous crystal Form I of the compound represented by Formula (I) was confirmed to have the following molecular structure (imino form) (details are described in Example 3).
  • a crystalline organic compound is composed of a large number of molecules arranged periodically in a three-dimensional space.
  • Structural periodicity typically develops physical properties that are clearly distinguishable by most spectroscopic probes (for example, X-ray diffraction, infrared spectrum, Raman spectrum, and solid-state NMR).
  • spectroscopic probes for example, X-ray diffraction, infrared spectrum, Raman spectrum, and solid-state NMR.
  • powder X-ray diffraction is one of the most sensitive analysis methods for measuring the crystallinity of a solid.
  • the X-rays When the crystal is irradiated with X-rays, the X-rays are reflected by the crystal lattice planes and interfere with each other, and only the diffraction rays in the direction satisfying the condition predicted by Bragg's law have increased in intensities, whereby ordered diffraction rays corresponding to the period of the structure are shown.
  • an amorphous solid an ordered diffraction ray is not observed.
  • An amorphous solid usually does not have an ordered repetition period in its structure, so that a diffraction phenomenon does not occur and shows a featureless broad XRPD pattern (also referred to as a halo pattern).
  • the crystalline form of the anhydride of the compound represented by Formula (I) can be characterized by a powder X-ray diffraction pattern and characteristic peaks.
  • the crystalline form of the anhydride of the compound represented by Formula (I) can be distinguished from other crystalline forms (for example, a hydrate crystal) by the presence of characteristic diffraction peaks.
  • Characteristic diffraction peaks used in the present specification are those selected from the observed diffraction patterns. In distinguishing a plurality of crystals, a peak that is observed in a crystal and is not observed in the other crystals, rather than the size of the peak, is a preferred characteristic peak in specifying the crystal. With such a characteristic peak, even one or two peaks can characterize the crystal. When the charts obtained by the measurement are compared and these characteristic peaks coincide with each other, it can be said that the powder X-ray diffraction spectra substantially coincide with each other.
  • the present invention encompasses not only crystals in which the diffraction angles of peaks in powder X-ray diffraction completely coincide with each other, but also crystals in which the diffraction angles of peaks coincide with each other with an error of about ⁇ 0.2°.
  • the intensities of the peaks displayed in the following tables and figures can vary depending on many factors, for example, the effect of a selective orientation of a crystal on X-ray beam, the effect of coarse particles, the purity of a material to be analyzed or the crystallinity of a sample.
  • Single crystal structure analysis (See Toshio SAKURAI, "X-sen Kozo Kaiseki no Tebiki (Guide to X-ray Structural Analysis)", published by Shokabo Co., Ltd. (1983 ), and Stout & Jensen, "X-Ray Structure Determination: A Practical Guide", Macmillan Co., New York (1968 ), etc.) is one of methods for determining a crystal, and it is possible to obtain crystallographic parameters in the crystal, atomic coordinates (values indicating a spatial positional relationship of each atom), and a three-dimensional structure model.
  • Single crystal structure analysis is useful for identifying the structure of the crystal of the composite as in the present invention.
  • a Raman spectrum shows vibrational features of molecules or a complex system. Its origin lies in inelastic collisions between molecules and photons as particles of light including light rays. The collision of molecules with photons leads to an exchange of energy, which results in a change in energy, which in turn changes the wavelength of the photons. That is, since the Raman spectrum are spectral line that are emitted when photons are incident on a target molecule and have an extremely narrow wavelength, a laser or the like is used as a light source. The wavelength of each Raman line is represented by a wavenumber shift from an incident light, which is a difference between an inverse of the wavelength of the Raman line and that of the incident light. The Raman spectrum is used for measuring a vibrational state of a molecule, which is determined by its molecular structure.
  • an absorption band (cm -1 ) in a Raman spectrum may have an error within a range of ⁇ 2cm -1
  • the value of the absorption peak should be understood as including a numerical value within a range of about ⁇ 2cm -1 . Therefore, the present invention encompasses not only crystals in which the peaks in the absorption bands in the Raman spectra completely coincide with each other, but also crystals in which the peaks in the absorption bands coincide with each other with an error of about ⁇ 2cm -1 .
  • the infrared absorption spectroscopy is a method for measuring, for each wavenumber, a degree of absorption of infrared rays when the infrared rays pass through a sample.
  • the infrared absorption spectrum is typically represented by a graph in which the horizontal axis represents a wavenumber and the vertical axis represents a transmittance or an absorbance.
  • the wavenumber and transmittance (or absorbance) of the absorption peak can be read on a graph, and values calculated by a data processing device can be used.
  • the infrared absorption spectrum is determined by the chemical structure of the substance. Therefore, absorption at various wavenumbers can be measured to confirm or quantify a substance.
  • the absorption bands for characteristic functional group are selected from about 20 absorption peaks, more preferably about 10 absorption peaks, and most preferably about 5 absorption peaks corresponding to the characteristic functional groups.
  • an absorption spectrum of a sample is measured in a wavenumber range of 4000cm -1 to 400cm -1 .
  • the absorption spectrum is measured under the same operating conditions as those when the resolution, the wavenumber scale, and the wavenumber accuracy of the apparatus were confirmed.
  • an absorption band (cm -1 ) in infrared absorption spectroscopy may have an error within a range of ⁇ 2cm -1
  • the value of the absorption peak should be understood as including a numerical value within a range of about ⁇ 2cm -1 . Therefore, the present invention encompasses not only crystals in which the peaks in the absorption bands in the infrared absorption spectroscopy completely coincide with each other, but also crystals in which the peaks in the absorption bands coincide with each other with an error of about ⁇ 2cm -1 .
  • Examples of the method for measuring an infrared absorption spectrum include the potassium bromide tablet method, the solution method, the paste method, a liquid film method, the thin film method, the gas sample measurement method, the ATR method, and the diffuse reflection method.
  • the attenuated total reflection (ATR) method is called the total reflection measurement method and is one of the reflection methods.
  • a sample is brought into close contact with a surface of a prism made of a substance having a high refractive index such as KRS-5, light is incident on the prism at an angle equal to or larger than a critical angle, and light totally reflected at a boundary between the prism and the sample is measured to obtain an absorption spectrum.
  • the refractive index of the prism is larger than that of the sample, and thus it is necessary to change the material of the prism depending on the sample.
  • the prism and the sample must be in close contact with each other. Therefore, it is suitable for measurement of liquid, powder, plastic, soft rubber, and the like, and there is an advantage that measurement can be performed without chemically or physically treating the sample.
  • the diffuse reflection method is a method of measuring a powder sample as it is without forming a potassium bromide tablet.
  • Solid state 13 C-NMR is useful for specifying a crystal form because (i) the number of spectra coincides with the number of carbon atoms of a target compound, (ii) the chemical shift range is wider than that of 1 H-NMR, (iii) a signal is sharper than that of solid state 1 H-NMR, and (iv) even if an additive is contained, the chemical shift does not change when there is no interaction. Note that an observed chemical shift is expected to vary slightly depending on the particular spectrometer used and the analyst's sample preparation technique. The error range in the solid 13 C-NMR spectrum is approximately ⁇ 0.5 ppm.
  • DSC is one of the main measurement methods of thermal analysis, and is a method for measuring thermal properties of a substance as an aggregate of atoms and molecules.
  • a differential scanning calorimetry curve is obtained by measuring a change in heat quantity with respect to temperature or time of the pharmaceutically active ingredient by DSC and plotting the obtained data with respect to temperature or time. From the differential scanning calorimetry curve, it is possible to obtain information on the onset temperature when the pharmaceutically active ingredient is melted, the maximum value of the endothermic peak curve associated with melting, and enthalpy.
  • the observed temperature may depend on temperature change rate as well as a sample preparation technique and specific equipment used.
  • the "melting point" in DSC refers to onset temperature that is less susceptible to sample preparation techniques.
  • An error range at the onset temperature obtained from the differential scanning calorimetry curve is approximately ⁇ 2°C. In recognition of the identity of crystals, not only the melting point but also the overall pattern is important, and the overall pattern may slightly vary depending on measurement conditions and a measuring instrument.
  • TG/DTA is one of the main measurement methods of thermal analysis, and is a method for measuring weight and thermal properties of a substance as an aggregate of atoms and molecules.
  • TG/DTA is a method for measuring changes in weight and heat quantity of a pharmaceutically active ingredient with respect to temperature or time, and curves of TG (thermogravimetry) and DTA (differential thermal analysis) are obtained by plotting the obtained data with respect to temperature or time. From the TG/DTA curves, it is possible to obtain information on weight and heat quantity change regarding decomposition, dehydration, oxidation, reduction, sublimation, and evaporation of the pharmaceutically active ingredient.
  • TG/DTA For TG/DTA, it is known that the observed temperature and weight change may depend on temperature change rate as well as a sample preparation technique and specific equipment used. Thus, the "melting point" in TG/DTA refers to onset temperature that is less susceptible to sample preparation techniques. In recognition of the identity of crystals, not only the melting point but also the overall pattern is important, and the overall pattern may slightly vary depending on measurement conditions and a measuring instrument.
  • the moisture adsorption/desorption isotherm measurement is a measurement method for measuring the adsorption and desorption behavior of moisture by measuring a weight change in a solid as a measurement target under each relative humidity condition.
  • the relative humidity is increased every 5% or 10%, and after the weight is stabilized at each relative humidity, the amount of adsorbed water can be determined from the weight increase from the reference value.
  • the desorption amount of water can be measured by decreasing the relative humidity every 5% or 10% from 100% RH.
  • Sorption and desorption of adhering water and crystal water are affected by particle size, crystallinity, crystal habit, and the like, so that the measurement results may slightly change.
  • the pharmaceutical composition containing a crystal of the present invention is very useful as a therapeutic agent or a prophylactic agent for chronic cough.
  • the crystal of the present invention can be administered to a human patient by itself, or can be administered as a pharmaceutical composition in which the crystal is mixed with an appropriate carrier or excipient.
  • Techniques for drug formulation and administration can be appropriately selected and used in combination with pharmaceutical formulations and techniques known to those skilled in the art.
  • Examples of administration route of the crystal of the present invention or the pharmaceutical composition containing the crystal can include, but is not limited to, oral, rectal, transmucosal, or intestinal administration, or intramuscular, subcutaneous, intraspinal, intrathecal, direct intraventricular, intravenous, intravitreal, intraperitoneal, intranasal, and intraocular, injection.
  • a preferred route of administration is oral administration.
  • the pharmaceutical composition of the present invention can be produced by a method well known in the art, for example, a process of conventional mixing, dissolving, granulating, sugar-coating, powdering, emulsifying, encapsulating, enclosing,or lyophilizing.
  • the crystal of the present invention or the pharmaceutical composition containing the crystal can be administered by injection using an aqueous solution, preferably a physiologically compatible buffer such as Ringer's solution or physiological saline.
  • a physiologically compatible buffer such as Ringer's solution or physiological saline.
  • the crystal of the present invention or the pharmaceutical composition containing the crystal can be administered transmucosally using a penetrant suitable for a barrier to be permeated.
  • a penetrant suitable for a barrier to be permeated.
  • the penetrant one generally known in the art can be used.
  • the crystal of the present invention or the pharmaceutical composition containing the crystal may be combined with a pharmaceutically acceptable carrier well known in the art so as to be orally administered.
  • a pharmaceutically acceptable carrier well known in the art so as to be orally administered.
  • the carrier allows the crystal of the invention to be administered as tablets, pills, lozenges, sugar-coated tablet, capsules, solution, gel, syrups, or suspensions.
  • Pharmaceutical compositions for oral administration can be made by adding solid excipients and, if desired, other suitable auxiliaries, followed by grinding the resulting mixture and processing the mixture of granules to obtain tablets or sugar-coated tablet cores.
  • Useful excipients are, in particular, fillers such as sugars, including lactose, sucrose, mannitol, or sorbitol, for example, cellulose preparations such as corn starch, wheat starch, rice starch, and potato starch, gelatin, gum tragacanth, methyl cellulose, hydroxypropylmethylcellulose, and/or sodium carboxymethylcellulose.
  • a disintegrant such as agar or alginic acid can be added.
  • a salt such as sodium alginate can also be used.
  • Examples of the pharmaceutical composition that can be used for oral administration include push-fit capsules made of gelatin, and sealed capsules made of gelatin and a plasticizer such as glycerol or sorbitol.
  • the push-fit capsule can contain an active ingredient mixed with a filler such as lactose, a binder such as starch, and/or a lubricant such as talc or magnesium stearate.
  • the pharmaceutical composition can also contain a suitable solid or a gel phase carrier or excipient.
  • a suitable solid or a gel phase carrier or excipient include calcium carbonate, calcium phosphate, various sugars, starch, cellulose derivatives, gelatin, and polymers such as polyethylene glycol.
  • a therapeutically effective amount can first be estimated from cell culture assay. Then, a dosage of a large amount can then be formulated for use in animal models to achieve a circulating concentration range that covers IC 50 (that is, a concentration of the crystal of the present invention or pharmaceutical composition thereof with which half maximal inhibition of PK activity is achieved) as determined in cell culture. Such information can then be used to more accurately determine a useful amount of the same in humans.
  • Therapeutic effects of the crystal of the present invention or the pharmaceutical composition thereof can be measured by a standard pharmaceutical method in cell culture or experimental animals. For example, evaluation may be performed according to a biological test method described in Patent Document 9. The data obtained from these cell culture assays and animal experiments can be used to formulate a range of dosages for use in humans. The dosage can be varied depending on the form of administration used and the route of administration utilized. The exact administration route of formulation and dosage can be selected by the individual physician in view of the patient's condition.
  • crystals of the present invention or pharmaceutical compositions thereof can be combined with other agents for the treatment of diseases and disorders.
  • the present invention provides an anhydride crystal or a hydrate crystal of the compound represented by Formula (I).
  • the crystalline solid has at least one of the following characteristics:
  • the crystalline solid of the present invention has high stability even in a wide humidity range (for example, 25 to 99% RH or the like) and a severe environment (for example, under high humidity).
  • halogen encompasses a fluorine atom, a chlorine atom, a bromine atom, and an iodine atom.
  • a fluorine atom and a chlorine atom are preferable.
  • alkyl encompasses a linear or branched hydrocarbon group having 1 to 15 carbon atoms, preferably 1 to 10 carbon atoms, more preferably 1 to 6 carbon atoms, and still more preferably 1 to 4 carbon atoms. Examples thereof include methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, sec-butyl, tert-butyl, n-pentyl, isopentyl, neopentyl, n-hexyl, isohexyl, n-heptyl, isoheptyl, n-octyl, isooctyl, n-nonyl, and n-decyl.
  • alkyl examples include methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, sec-butyl, tert-butyl, and n-pentyl. More preferred embodiments include methyl, ethyl, n-propyl, isopropyl, and tert-butyl.
  • C1-C4 alkyl examples include methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, sec-butyl, and tert-butyl.
  • the present invention includes a step of producing a compound represented by Formula (IV): wherein R 1 is C1-C4 alkyl, or a salt thereof, characterized by causing a reaction between a compound represented by Formula (II): or a salt thereof, and a compound represented by Formula (III): wherein R 1 is C1-C4 alkyl,
  • the compound represented by Formula (II) or a salt thereof and the compound represented by Formula (III) or a salt thereof can be produced according to a known method from commercially available reagents, or a commercially available product can be used as these compounds and salts.
  • the solvent is not particularly limited as long as the reaction is not inhibited, but methanol, ethanol, isopropyl alcohol, t-butanol, or a mixed solvent thereof can be used as the solvent.
  • methanol can be used.
  • the reaction is usually carried out in a range of room temperature to a temperature at which the solvent is refluxed.
  • the reaction can be performed in a range of -10°C to a temperature at which the solvent is refluxed.
  • it can be performed at 80°C.
  • the reaction time is 1 to 20 hours, for example, 5 to 7 hours.
  • the use amount of the compound represented by Formula (III) with respect to the compound represented by Formula (II) can be usually 1.0 to 10.0 equivalents, for example, 2.0 to 4.0 equivalents, for example, 3.0 equivalents.
  • lithium chloride calcium chloride, magnesium chloride, lithium bromide, p-toluenesulfonic acid, methanesulfonic acid, trifluoromethanesulfonic acid, or the like can be used.
  • a plurality of these additives can be selected and used simultaneously.
  • the use amount of the additive with respect to the compound represented by Formula (II) can be usually 0.1 to 5.0 equivalents, for example, 1.0 to 2.0 equivalents, for example, 1.0 to 1.5 equivalents.
  • the present invention includes a step of producing a p-toluenesulfonic acid salt of a compound represented by Formula (IV-A): wherein R 1 is C1-C4 alkyl, characterized by: adding p-toluenesulfonic acid to a compound represented by Formula (IV): wherein R 1 is C1-C4 alkyl, or a salt thereof.
  • the use amount of p-toluenesulfonic acid monohydrate (or aqueous p-toluenesulfonic acid solution) with respect to the compound represented by Formula (II) can be usually 0.5 to 2.0 equivalents, for example, 0.8 to 1.0 equivalents.
  • the present invention includes a step of producing a 1/2 sulfuric acid salt of a compound represented by Formula (V): characterized by: subjecting a p-toluenesulfonic acid salt of a compound represented by Formula (IV-B): to a hydrogenolysis reaction; and adding sulfuric acid thereto.
  • the compound represented by Formula (IV-B) can be produced according to the above-described step.
  • the solvent is not particularly limited as long as the reaction is not inhibited, but methanol, ethanol, 1-propanol, isopropyl alcohol, t-butanol, tetrahydrofuran, or a mixed solvent thereof can be used.
  • methanol can be used.
  • the reaction is usually carried out in a range of room temperature to a temperature at which the solvent is refluxed.
  • the reaction can be performed in a range of room temperature to a temperature at which the solvent is refluxed.
  • it can be performed at 30 to 50°C.
  • the reaction time is 30 minutes to 20 hours, for example, 1 to 3 hours.
  • hydrolysis reaction catalyst palladium carbon, palladium hydroxide, palladium black, or the like can be used.
  • the use amount of the hydrolysis reaction catalyst with respect to the compound represented by Formula (IV-B) can be usually 0.01 to 1 w/w, for example, 0.1 to 0.3 w/w.
  • the use amount of concentrated sulfuric acid with respect to the compound represented by Formula (IV-B) can be usually 0.01 to 5.0 equivalents, for example, 0.3 to 0.4 equivalents.
  • the present method includes a step of producing a compound represented by Formula (I): or a salt thereof, characterized by: subjecting the compound represented by Formula (VI): wherein R 1 is C1-C4 alkyl,
  • the compound represented by Formula (VI) can be produced according to the above-mentioned steps and the methods described in Patent Documents 6, 7, 8 and 9.
  • the solvent is not particularly limited as long as the reaction is not inhibited, but isopropyl alcohol (2-propanol), tetrahydrofuran, and t-butanol, or a mixed solvent thereof can be used.
  • isopropyl alcohol (2-propanol) can be used.
  • the reaction is usually carried out in a range of -10°C to a temperature at which the solvent is refluxed. For example, it can be performed at 30°C to 40°C.
  • the reaction time is 0.1 to 20 hours, for example, 1 to 5 hours.
  • sodium hydroxide potassium hydroxide, lithium hydroxide, or the like can be used.
  • sodium hydroxide can be used.
  • the use amount of a base with respect to the compound represented by Formula (VI) can be usually 2.0 to 5.0 equivalents, for example, 2.0 to 3.0 equivalents.
  • % means % by weight of the component and % by weight of the total weight of the composition
  • pressure means a pressure at or near atmospheric pressure
  • Powder X-ray diffraction measurement of a crystal obtained in each Example was performed according to the powder X-ray diffraction measurement method described in "General Tests, Processes, and Apparatus" of Japanese Pharmacopoeia. The measurement conditions are shown below.
  • Measurement apparatus LabRAM ARAMIS (manufactured by HORIBA Jobin Yvon SAS)
  • a DSC of a crystal obtained in each Example was measured. About 4.199 mg of a sample was weighed in an aluminum pan, and the weight was measured by simple sealing. The measurement conditions are shown below. Incidentally, an error may occur within a range of ⁇ 2°C in the measurement by differential scanning calorimetry (DSC).
  • DSC differential scanning calorimetry
  • HPLC The retention time of HPLC should be understood as including some errors.
  • Example 7 About 4.4 mg of the crystal obtained in Example 7 was weighed, was put in an aluminum pan, and was measured in an open system.
  • the measurement conditions are as follows.
  • the data were subjected to Lorentz, and polarization correction, and absorption correction.
  • the phase determination was performed using the direct method program ShelXT (Sheldrick, G.M., 2015), and was refined by the full-matrix least squares method using ShelXL (Sheldrick, G.M., 2015). All temperature factors of non-hydrogen atoms were refined with anisotropy.
  • a hydrogen atom H5 on an oxygen O5 was derived from a difference Fourier map and refined. The remaining hydrogen atoms were introduced by calculation using default parameters of ShelXL and treated as riding atoms. All hydrogen atoms were refined with isotropic parameters.
  • R1 (I>2.00s(I)) was 0.0470, and it was confirmed from the final difference Fourier that there was neither lacking nor erroneous electron density.
  • Toluene (61.04 g) was added to the obtained aqueous layer at room temperature, and an aqueous layer was removed by liquid separation. The obtained two organic layers were combined, toluene (16.99 g) was added, and the mixture was concentrated under reduced pressure at 50°C.
  • Toluene (155.91 g) was added to the concentrate prepared above.
  • the ethanol solution (5.88 g) of p-toluenesulfonic acid prepared above and a slurry of seed crystal (19.95 mg, 0.05070 mmol) in toluene (63 ⁇ L) were added to the mixture at room temperature to give a slurry of the compound (3).
  • Remaining ethanol solution (39.93 g) of the p-toluenesulfonic acid prepared above was added to the obtained slurry, and ethanol (10 mL) was added thereto.
  • the resulting mixture was stirred for 2 hours and allowed to stand overnight.
  • the mixture was cooled to 0°C and stirred for 2 hours, and a solid was collected by filtration, to give the compound (3) (20.75 g, 31.9%) as a crude product.
  • the compound (4) (19.00 g, 114.3 mmol) was suspended in acetonitrile (45.00 g). At 2°C, 1,8-diazabicyclo[5.4.0]-7-undecene (19.10 g, 125.5 mmol) and acetonitrile (3.00 g) were added thereto, and the mixture was stirred at 2°C for 30 minutes.
  • the reaction solution was added, at 2°C, to a slurry obtained by suspending N,N-carbonyldiimidazole (21.30 g, 131.4 mmol) in acetonitrile (75.00 g). Acetonitrile (15.00 g) was added to the reaction solution, and the mixture was stirred at 2°C for 1 hour and 22 minutes.
  • the reaction solution was concentrated under reduced pressure at 50°C. N, N-Dimethylacetamide (27.00 g) was added to the obtained concentrated solution, the mixture was cooled to 10°C, and 17% aqueous sulfuric acid (204.1 g) and water (19.00 g) were added thereto. To the reaction solution, 17% aqueous sulfuric acid (31.30 g) and water (2.50 g) were added at 25°C, and the mixture was stirred for 1 hour and 48 minutes. The reaction solution was concentrated under reduced pressure at 50°C. Water (190 mL) was added to the obtained concentrated solution and cooled to 2°C, and then 17% aqueous sulfuric acid (3.30 g) and water (1.30 g) were added thereto. The reaction solution was stirred at 2°C for 1 hour and 15 minutes, and the precipitated solid was collected by filtration to obtain a compound (5) (27.13 g, 85.0%).
  • the mixture was stirred at 115°C for 2 hours and 35 minutes, and then cooled to 50°C.
  • Water (7.50 g) was added to the reaction solution at 50°C, and thereafter the reaction solution was cooled to 25°C.
  • Water (67.54 g) was added thereto, and was cooled to 1°C for crystallization.
  • the precipitated solid was collected by filtration to obtain a seed crystal (3.84 g, 65.2%) of the compound (8).
  • N,N-dimethylacetamide solution of 4-chlorobenzyl chloride prepared by dissolving 4-chlorobenzyl chloride (6.43 g, 39.9 mmol) in N,N-dimethylacetamide (9.56 g) was added at 75°C, and N,N-dimethylacetamide (9.56 g) was added.
  • the reaction solution was stirred at 75°C for 5 hours and 15 minutes.
  • the reaction solution was cooled to 25°C, acetic acid (0.65 g, 11 mmol) was added thereto, and the mixture was heated to 40°C.
  • N,N-dimethylacetamide solution of the compound (8) prepared by dissolving the compound (8) (7.43 g, 39.9 mmol) in N, N-dimethylacetamide (9.55 g) was added, and N, N-dimethylacetamide (9.55 g) was added.
  • the reaction solution was stirred at 40°C for 3 hours, and was cooled to room temperature.
  • acetone (27.94 g) and water (35.46 g) were added.
  • a seed crystal (10.13 mg) of the compound (9), water (0.40 g), and acetone (0.08 g) were added to the reaction solution, and the mixture was stirred at room temperature for 3 hours and 25 minutes and then left overnight.
  • an N,N-dimethylacetamide solution of 4-chlorobenzyl chloride prepared by dissolving 4-chlorobenzyl chloride (3.16 g, 19.6 mmol) in N,N-dimethylacetamide (4.71 g) was added at 75°C, and N,N-dimethylacetamide (4.71 g) was added.
  • the reaction solution was stirred at 75°C for 4 hours and 30 minutes.
  • the reaction solution was cooled to 25°C, acetic acid (0.32 g, 5.3 mmol) was added thereto, and the mixture was heated to 40°C.
  • Main absorption peaks are recognized at 829cm -1 ⁇ 2cm -1 , 989cm -1 ⁇ 2cm -1 , 1013cm -1 ⁇ 2cm -1 , 1093cm -1 ⁇ 2cm -1 , 1128cm -1 ⁇ 2cm -1 , 1243cm -1 ⁇ 2cm -1 , 1370cm -1 ⁇ 2cm -1 , 1599cm -1 ⁇ 2cm -1 , 1659cm -1 ⁇ 2cm -1 , 1735cm -1 ⁇ 2cm -1 , 2938cm -1 ⁇ 2cm -1 , and 3067cm -1 ⁇ 2cm -1 .
  • the anhydrous crystal Form I of the compound represented by Formula (I) has absorption peaks at 829cm -1 ⁇ 2cm -1 , 989cm -1 ⁇ 2cm -1 , 1013cm -1 ⁇ 2cm -1 , 1128cm -1 ⁇ 2cm -1 , and 1370cm -1 ⁇ 2cm -1 .
  • the anhydrous crystal Form I of the compound represented by Formula (I) has an absorption peak at 829cm -1 ⁇ 2cm -1 .
  • the anhydrous crystal Form I of the compound represented by Formula (I) has an absorption peak at 989cm -1 ⁇ 2cm -1 .
  • the anhydrous crystal Form I of the compound represented by Formula (I) has an absorption peak at 1013cm -1 ⁇ 2cm -1 .
  • the anhydrous crystal Form I of the compound represented by Formula (I) has an absorption peak at 1128cm -1 ⁇ 2cm -1 .
  • the anhydrous crystal Form I of the compound represented by Formula (I) has an absorption peak at 1370cm -1 ⁇ 2cm -1 .
  • the anhydrous crystal Form I of the compound represented by Formula (I) has one or more absorption peaks selected from the group consisting of an absorption peak at 829cm -1 ⁇ 2cm -1 , an absorption peak at 989cm -1 ⁇ 2cm -1 , an absorption peak at 1013cm -1 ⁇ 2cm -1 , an absorption peak at 1128cm -1 ⁇ 2cm -1 , and an absorption peak at 1370cm -1 ⁇ 2cm -1 .
  • V represents a volume of a unit lattice
  • Z represents the number of molecules in the unit lattice
  • Atomic coordinates of non-hydrogen atoms are shown in Tables 5 to 7.
  • U (eq) means an equivalent isotropic temperature factor.
  • Atomic coordinates of hydrogen atoms are shown in Tables 8 and 9.
  • U (iso) means an isotropic temperature factor.
  • the numbers of hydrogen atoms in Table 8 and 9 were assigned in relation to the numbers of non-hydrogen atoms bonded thereto.
  • the bond distance of C12-N2 was about 1.26 ⁇
  • the bond distance of C37-N7 was about 1.27 ⁇ .
  • A1, A3', and A3" represent peak areas in HPLC measurement, respectively.
  • the compound (3") has the following chemical structural formula.
  • Non-Patent Document 16 Only the reaction conditions for heating and refluxing for 9 days as described in Non-Patent Document 16 have been known, but the reaction is accelerated in the presence of these additives, and is completed in a short time of 1 hour to 7 hours, so that it can be said that the present process method is an industrially excellent process method.
  • Non-Patent Document 16 after completion of the aza-Michael addition reaction of (S)-1-phenylethylamine ((S)- ⁇ -methylbenzylamine) and methyl methacrylate, p-toluenesulfonic acid is added to obtain a p-toluenesulfonic acid salt.
  • p-toluenesulfonic acid is added to obtain a p-toluenesulfonic acid.
  • Non-Patent Document 16 the p-toluenesulfonic acid salt of an enantiomer of Formula (IV-B) of the present application is obtained, and thus the present invention is not described in Non-Patent Document 16:
  • Ms, M L , As, and A L represent peak areas in HPLC measurement, respectively.
  • M S weighed amount (mg) of an isolated solid of hydrochloride of compound (4') or sulfate of compound (4') in HPLC measurement
  • M L weighed amount (mg) of filtrate in HPLC measurement
  • a S peak area of an isolated solid of hydrochloride of compound (4') or sulfate of compound (4') in HPLC measurement
  • a L peak area of filtrate in HPLC measurement
  • the method for producing the compound (4') as a sulfate is an industrially excellent process method because the amount of the free form eluted in the filtrate is small, which means that the loss during process is small.
  • Patent Documents 6, 7, 8, and 9 disclose a process method for obtaining a carboxylic acid by hydrolyzing an ester, and as a solvent, dioxane, THF, DMSO, a MeOH-THF mixed solution, a THF-EtOH-water mixed solution, a MeOH-water mixed solution, a MeOH-THF-water mixed solution, or the like is used.
  • the R form amount of the compound (9) was calculated by the following formula.
  • the unit represents a peak area (%). Area % or R isomer of compound 9 Area % of compound 9 + Area % of R isomer of compound 9 ⁇ 100
  • R isomer amount of the compound represented by Formula (I) was calculated by the following formula.
  • the unit represents a peak area (%).
  • Area % or R isomer of compound represented by Formula I Area % of compound represented by Formula I + Area % of R isomer of compound represented by Formula I ⁇ 100
  • the structural formulae of the R isomer of the compound (9) and the R isomer of the compound represented by Formula (I) are as follows.
  • the molecular structures (amino form/imino form) of the R isomer of the compound (9) and the R isomer of the compound represented by Formula (I) have not been determined.
  • the dihydrate crystal was confirmed by thermogravimetry/differential thermal analysis (TG/DTA), moisture absorption and desorption measurement (DVS), and powder X-ray diffraction measurement.
  • a powder X-ray diffraction pattern of the dihydrate crystal of the compound represented by Formula (I) is shown in Fig. 4 (Method 1).
  • Peaks at diffraction angles of 5.7° ⁇ 0.2°, 7.7° ⁇ 0.2°, 11.8° ⁇ 0.2°, 15.2° ⁇ 0.2°, 17.7° ⁇ 0.2°, 20.6° ⁇ 0.2°, 20.8° ⁇ 0.2°, 26.5° ⁇ 0.2°, 27.1° ⁇ 0.2°, and 29.1° ⁇ 0.2° are particularly characteristic of the dihydrate crystal of the compound represented by Formula (I).
  • Main absorption peaks are recognized at 871cm -1 ⁇ 2cm -1 , 996cm -1 ⁇ 2cm -1 , 1093cm -1 ⁇ 2cm -1 , 1114cm -1 ⁇ 2cm -1 , 1234cm -1 ⁇ 2cm -1 , 1248cm -1 ⁇ 2cm -1 , 1340cm -1 ⁇ 2cm -1 , 1577cm -1 ⁇ 2cm -1 , 1603cm -1 ⁇ 2cm -1 , 1662cm -1 ⁇ 2cm -1 , 1738cm -1 ⁇ 2cm -1 , 2971cm -1 ⁇ 2cm -1 , and 3073cm -1 ⁇ 2cm -1 .
  • the dihydrate crystal of the compound represented by Formula (I) has absorption peaks at 871cm -1 ⁇ 2cm -1 , 996cm -1 ⁇ 2cm -1 ,1114cm -1 ⁇ 2cm -1 , 1234cm -1 ⁇ 2cm -1 , 1340cm -1 ⁇ 2cm -1 , and 1577cm -1 ⁇ 2cm -1 .
  • the dihydrate crystal of the compound represented by Formula (I) has an absorption peak at 871cm -1 ⁇ 2cm -1 .
  • the dihydrate crystal of the compound represented by Formula (I) has an absorption peak at 996cm -1 ⁇ 2cm -1 .
  • the dihydrate crystal of the compound represented by Formula (I) has an absorption peak at 1114cm -1 ⁇ 2cm -1 .
  • the dihydrate crystal of the compound represented by Formula (I) has an absorption peak at 1234cm -1 ⁇ 2cm -1 .
  • the dihydrate crystal of the compound represented by Formula (I) has an absorption peak at 1340cm -1 ⁇ 2cm -1 .
  • the dihydrate crystal of the compound represented by Formula (I) has an absorption peak at 1577cm -1 ⁇ 2cm -1 .
  • the dihydrate crystal of the compound represented by Formula (I) has one or more absorption peaks selected from the group consisting of an absorption peak at 871cm -1 ⁇ 2cm -1 , an absorption peak at 996cm -1 ⁇ 2cm -1 ,an absorption peak at 1114cm -1 ⁇ 2cm -1 , an absorption peak at 1234cm -1 ⁇ 2cm -1 , an absorption peak at 1340cm -1 ⁇ 2cm -1 , and an absorption peak at 1577cm -1 ⁇ 2cm -1 .
  • thermogravimetry/differential thermal analysis TG/DTA
  • Fig. 5 The results of the thermogravimetry/differential thermal analysis (TG/DTA) of the dihydrate crystals of the compound represented by Formula (I) are shown in Fig. 5 .
  • TG/DTA thermogravimetry/differential thermal analysis
  • a formic acid aqueous solution prepared by mixing formic acid (8.64 g, 188 mmol) and water (70.00 g) was added dropwise at 25°C, and then water (7.00 g) and methanol (27.70 g) were added thereto.
  • the obtained slurry was filtered to obtain a seed crystal of a dihydrate (64.04 g) of the compound represented by Formula (I).
  • each step for producing the compound 1-127 is not specifically described in Patent Document 9.
  • the compound I-127 was synthesized in the same manner as the similar compound of the compound I-127 (Reference Example 3 of Patent Document 9). Only the final step is shown below.
  • Methyl (S,E)-3-(3-(4-chlorobenzyl)-2,6-dioxo-4-((4-(pyridin-2-yloxy)phenylhmino)-1,3,s-triazinan-1-yl)-2-methylpropanoate (0.365 g, 0.7 mmol), MeOH (1 mL), THF (1 mL), H 2 O (1 mL), and a 4 mol/L-LiOH aqueous solution (0.7 mL, 2.80 mmol) were mixed, and the mixture was stirred at room temperature for 2 hours.
  • the reaction solution was added to a half saturated brine (100 mL) and a 5% citric acid solution, and the mixture was extracted with ethyl acetate (100 mL), then an organic layer was washed with a half saturated brine (100 mL). The organic layer was dried over magnesium sulfate and then distilled off under reduced pressure.
  • Main absorption peaks are recognized at 821cm -1 ⁇ 2cm -1 , 856cm -1 ⁇ 2cm -1 , 893cm -1 ⁇ 2cm -1 , 1002cm -1 ⁇ 2cm -1 , 1094cm -1 ⁇ 2cm -1 , 1221cm -1 ⁇ 2cm -1 , 1269cm -1 ⁇ 2cm -1 , 1575cm -1 ⁇ 2cm -1 , 1604cm -1 ⁇ 2cm -1 , 1614cm -1 ⁇ 2cm -1 , 1649cm -1 ⁇ 2cm -1 , 1725cm -1 ⁇ 2cm -1 , and 3073cm -1 ⁇ 2cm -1 .
  • Main absorption peaks are recognized at 821cm -1 ⁇ 2cm -1 , 1002cm -1 ⁇ 2cm -1 , 1269cm -1 ⁇ 2cm -1 , 1575cm -1 ⁇ 2cm -1 , 1614cm -1 ⁇ 2cm -1 , 1649cm -1 ⁇ 2cm -1 , and 1725cm -1 ⁇ 2cm -1 .
  • Main absorption peaks are recognized at 1575cm -1 ⁇ 2cm -1 , 1614cm -1 ⁇ 2cm -1 , and 1649cm -1 ⁇ 2cm -1 .
  • Main absorption peaks are recognized at 1614cm -1 ⁇ 2cm -1 , and 1649cm -1 ⁇ 2cm -1 .
  • An anhydrous crystal Form I (about 10 mg) of the compound represented by Formula (I) was weighed in a vial, and 200 ⁇ L of CHCl 3 was added thereto. The mixture was stirred with a magnetic stirrer at 400 rpm at 25°C (overnight operation). After 7 days, the mixture was filtered, and the obtained powder was confirmed by powder X-ray diffraction measurement.
  • Hexane is a solvent (class 2) whose residual amount in the active pharmaceutical ingredient should be regulated, and ethyl acetate is a low-toxicity solvent (class 3). Therefore, it is necessary to adjust the residual amount of hexane in the active pharmaceutical ingredient to a specified value or less.
  • Table 17 below shows solvents of class 2 listed in the ICH Q3C guideline.
  • Permitted Daily Exposure (PDE) of hexane is 2.9 mg/day.
  • the PDE of hexane may be equal to or more than the regulation value depending on the dose.
  • the anhydrous crystal Form I and the dihydrate crystal of the compound represented by Formula (I) did not contain hexane as a residual solvent, and was found to be excellent as a crystal form used for an active pharmaceutical ingredient.
  • the residual ratio was 99% or more, and it was found to be a stable crystal form.
  • the ethyl acetate/hexane solvate crystal of the compound represented by Formula (I) five types of analogous substances were generated.
  • the anhydrous crystal Form I of the compound represented by Formula (I) three types of analogous substances were generated, and in the dihydrate crystal of the compound represented by Formula (I), two types of analogous substances were generated. From the above, it was found that in the anhydrous crystal Form I and the dihydrate crystal of the compound represented by Formula (I), there are few types of analogous substance to be generated.
  • the compound of the invention can be administered as a pharmaceutical composition by any conventional route, in particular enterally, for example orally, for example in the form of a tablet or a capsule, or parenterally, for example in the form of an injectable or a suspension; topically, for example in the form of a lotion, gel, ointment or cream; or in a nasal or suppository form.
  • a pharmaceutical composition containing the compound of the invention in a free form or in a form of a pharmaceutically acceptable salt together with at least one pharmaceutically acceptable carrier or diluent can be produced in a conventional manner by mixing, granulating or coating.
  • the oral composition can be a tablet, a granule, or a capsule containing an excipient, a disintegrant, a binder, a lubricant, or the like, as well as an active ingredient, or the like.
  • the injectable composition may be a solution or a suspension, may be sterilized, or may contain a preservative, a stabilizer, a buffering agent, or the like.
  • the crystal of the compound represented by Formula (I) as the present invention is useful as an active pharmaceutical ingredient.
  • the pharmaceutical composition containing the crystal of the compound represented by Formula (I) is very useful as a therapeutic agent or a prophylactic agent for chronic cough.
  • the present invention is useful as a method for producing the compound represented by Formula (I).
EP20865547.2A 2019-09-19 2020-09-18 Cristal de dérivé de 1,3,5-triazine ou solvate de celui-ci et son procédé de production Pending EP4032884A4 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2019170340 2019-09-19
JP2020122749 2020-07-17
PCT/JP2020/035378 WO2021054421A1 (fr) 2019-09-19 2020-09-18 Cristal de dérivé de 1,3,5-triazine ou solvate de celui-ci et son procédé de production

Publications (2)

Publication Number Publication Date
EP4032884A1 true EP4032884A1 (fr) 2022-07-27
EP4032884A4 EP4032884A4 (fr) 2023-09-13

Family

ID=74884075

Family Applications (1)

Application Number Title Priority Date Filing Date
EP20865547.2A Pending EP4032884A4 (fr) 2019-09-19 2020-09-18 Cristal de dérivé de 1,3,5-triazine ou solvate de celui-ci et son procédé de production

Country Status (11)

Country Link
US (1) US20220396561A1 (fr)
EP (1) EP4032884A4 (fr)
JP (1) JP6873534B1 (fr)
KR (1) KR20220066307A (fr)
CN (2) CN114728931A (fr)
AU (1) AU2020348089A1 (fr)
BR (1) BR112022004398A2 (fr)
CA (1) CA3155142A1 (fr)
MX (1) MX2022002941A (fr)
TW (1) TW202124373A (fr)
WO (1) WO2021054421A1 (fr)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20230183205A1 (en) 2020-05-15 2023-06-15 Shionogi & Co., Ltd. Pharmaceutical composition in which production of impurities is suppressed

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2249589T3 (es) 2001-05-18 2006-04-01 Abbott Laboratories Trisustituido-n-((1s)-1,2,3,4-tetrahidro-1-naftalenil)benzamidas que inhiben receptores que contienen antagonistas p2x3 y p2x2/3.
US20060029548A1 (en) 2004-07-22 2006-02-09 Amir Pelleg Methods of diagnosing, monitoring and treating pulmonary diseases
PT2399910E (pt) * 2009-02-13 2014-05-02 Shionogi & Co Novo derivado de triazina e composição farmacéutica que contém o mesmo
JP5476467B2 (ja) 2009-06-22 2014-04-23 エフ．ホフマン−ラ ロシュ アーゲー 新規なビフェニルピリジンアミドおよびフェニルピリジンアミド
US9718790B2 (en) 2010-08-10 2017-08-01 Shionogi & Co., Ltd. Triazine derivative and pharmaceutical composition having an analgesic activity comprising the same
WO2013089212A1 (fr) * 2011-12-15 2013-06-20 塩野義製薬株式会社 Dérivé de triazine substituée et composition pharmaceutique le contenant
US10201670B2 (en) * 2012-10-25 2019-02-12 Fisher & Paykel Healthcare Limited Pressure relief arrangement for open surgery insufflation system
TWI637949B (zh) * 2013-06-14 2018-10-11 塩野義製藥股份有限公司 胺基三衍生物及含有其等之醫藥組合物
EP3865134A1 (fr) 2013-08-23 2021-08-18 Afferent Pharmaceuticals Inc. Procédés d'utilisation de diaminopyrimidines en tant que modulateurs des récepteurs p2x3 et p2x 2/3 pour le traitement de la toux aiguë, subaiguë ou chronique dans des maladies respiratoires
EP4215182A1 (fr) 2015-09-29 2023-07-26 Afferent Pharmaceuticals Inc. Modulateurs des récepteurs p2x3 et p2x2/3 de diaminopyrimidine destinés à être utilisés dans le traitement de la toux
BR112021005334A2 (pt) 2018-10-05 2021-06-15 Shionogi & Co., Ltd. medicamento para tratamento de tosse crônica
US20230183205A1 (en) * 2020-05-15 2023-06-15 Shionogi & Co., Ltd. Pharmaceutical composition in which production of impurities is suppressed

Also Published As

Publication number Publication date
KR20220066307A (ko) 2022-05-24
TW202124373A (zh) 2021-07-01
AU2020348089A1 (en) 2022-03-31
CN117843615A (zh) 2024-04-09
WO2021054421A1 (fr) 2021-03-25
MX2022002941A (es) 2022-04-06
BR112022004398A2 (pt) 2022-05-31
JP6873534B1 (ja) 2021-05-19
CA3155142A1 (fr) 2021-03-25
EP4032884A4 (fr) 2023-09-13
US20220396561A1 (en) 2022-12-15
JPWO2021054421A1 (ja) 2021-09-30
CN114728931A (zh) 2022-07-08

Similar Documents

Publication Publication Date Title
KR102494188B1 (ko) 바이러스 증식 저해 작용을 갖는 트라이아진 유도체 및 그들을 함유하는 의약 조성물
WO2017135471A1 (fr) INHIBITEUR DE L'INTÉGRINE α4β7
JP7261529B1 (ja) ウイルス増殖阻害作用を有するトリアジン誘導体の製造方法
EP4032884A1 (fr) Cristal de dérivé de 1,3,5-triazine ou solvate de celui-ci et son procédé de production
US20120283274A1 (en) Crystalline forms of substituted pyrazolopyrimidines
JP2023512471A (ja) Ｐｄｅ３／ｐｄｅ４二重阻害剤の結晶及びその使用
WO2021063276A1 (fr) Dérivé macrocyclique, son procédé de préparation et utilisation associée
Sun Improved solubility of gefitinib achieved by the water-acetone solvate
RU2806042C1 (ru) Триазиновые производные, имеющие ингибиторную активность в отношении репликации вируса, и содержащая их фармацевтическая композиция
US20200308103A1 (en) Novel crystals of hydroxamic acid derivative, production method thereof, and pharmaceutical composition
US20230034132A1 (en) Crystal form as inhibitor of acc1 and acc2, and preparation method therefor and use thereof
EP3677581A1 (fr) Inhibiteur de l'indoléamine 2,3-dioxygénase deutéré et son application
BR122023002208A2 (pt) Composições farmacêuticas compreendendo derivados de triazina tendo efeito inibidor de propagação de vírus, inibidores e usos
KR20240004588A (ko) 피롤로피리미딘류 화합물의 결정형 및 이의 제조 방법
CN116903627A (zh) 一种咪唑并三嗪硫代苯甲酰胺衍生物及其制备方法和应用
CN109996800A (zh) 吡啶并[3,4-d]嘧啶衍生物或其溶剂合物的晶体
TW201625580A (zh) 吡啶衍生物的新穎結晶多形體及其製造方法

Legal Events

Date Code Title Description
STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE

PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE

17P Request for examination filed

Effective date: 20220331

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

DAV Request for validation of the european patent (deleted)
DAX Request for extension of the european patent (deleted)
A4 Supplementary search report drawn up and despatched

Effective date: 20230811

RIC1 Information provided on ipc code assigned before grant

Ipc: A61P 43/00 20060101ALI20230807BHEP

Ipc: A61P 25/04 20060101ALI20230807BHEP

Ipc: A61P 13/02 20060101ALI20230807BHEP

Ipc: A61P 11/00 20060101ALI20230807BHEP

Ipc: A61P 9/12 20060101ALI20230807BHEP

Ipc: A61K 31/53 20060101ALI20230807BHEP

Ipc: C07D 401/12 20060101AFI20230807BHEP